Science Advances-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2258525, encodeId=7b88225852589, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：代谢工程;合成生物学;发酵调控 经验分享：24号开始 Under Evaluation，26，28分别动了一下日期，今天31号还是Under Evaluation，点进去看发现Editor Evaluation Completed，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26e69688758, createdName=ms3000001687948380, createdTime=Mon Mar 31 15:13:14 CST 2025, time=2025-03-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248945, encodeId=d92c22489452e, content=在home页面显示Under Evaluation，但是点进去文章稿件名之后，显示Status: Reviewer Invited是已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Mon Jan 20 22:44:21 CST 2025, time=2025-01-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=550438, encodeId=32c7550438f6, content=Nature Communications: 73591/(6721+15) = 10.925 Science Advances: 6814/(726+15) = 9.195 Developmental Cell: 3635/(372+38) = 8.865 PNAS: 55771/6468 = 8.622 Cell Reports: 13710/1866 = 7.347 eLife: 13222/1979 = 6.681 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96201620396, createdName=CR10, createdTime=Thu Dec 28 20:46:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2236836, encodeId=910d223683628, content=审稿速度:3.0 经验分享：12, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45909346082, createdName=ms8000001611048358, createdTime=Thu Nov 14 00:15:36 CST 2024, time=2024-11-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=867, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=483, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给我们的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=421, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省)]

2025-03-31 ms3000001687948380 来自浙江省

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：代谢工程;合成生物学;发酵调控
经验分享：24号开始 Under Evaluation，26，28分别动了一下日期，今天31号还是Under Evaluation，点进去看发现Editor Evaluation Completed，是不是要被拒了

11 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2258525, encodeId=7b88225852589, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：代谢工程;合成生物学;发酵调控 经验分享：24号开始 Under Evaluation，26，28分别动了一下日期，今天31号还是Under Evaluation，点进去看发现Editor Evaluation Completed，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26e69688758, createdName=ms3000001687948380, createdTime=Mon Mar 31 15:13:14 CST 2025, time=2025-03-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248945, encodeId=d92c22489452e, content=在home页面显示Under Evaluation，但是点进去文章稿件名之后，显示Status: Reviewer Invited是已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Mon Jan 20 22:44:21 CST 2025, time=2025-01-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=550438, encodeId=32c7550438f6, content=Nature Communications: 73591/(6721+15) = 10.925 Science Advances: 6814/(726+15) = 9.195 Developmental Cell: 3635/(372+38) = 8.865 PNAS: 55771/6468 = 8.622 Cell Reports: 13710/1866 = 7.347 eLife: 13222/1979 = 6.681 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96201620396, createdName=CR10, createdTime=Thu Dec 28 20:46:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2236836, encodeId=910d223683628, content=审稿速度:3.0 经验分享：12, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45909346082, createdName=ms8000001611048358, createdTime=Thu Nov 14 00:15:36 CST 2024, time=2024-11-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=867, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=483, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给我们的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=421, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省)]

2025-01-20 ms8000001656880339 来自北京

在home页面显示Under Evaluation，但是点进去文章稿件名之后，显示Status: Reviewer Invited是已经送审了吗？

31 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2258525, encodeId=7b88225852589, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：代谢工程;合成生物学;发酵调控 经验分享：24号开始 Under Evaluation，26，28分别动了一下日期，今天31号还是Under Evaluation，点进去看发现Editor Evaluation Completed，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26e69688758, createdName=ms3000001687948380, createdTime=Mon Mar 31 15:13:14 CST 2025, time=2025-03-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248945, encodeId=d92c22489452e, content=在home页面显示Under Evaluation，但是点进去文章稿件名之后，显示Status: Reviewer Invited是已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Mon Jan 20 22:44:21 CST 2025, time=2025-01-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=550438, encodeId=32c7550438f6, content=Nature Communications: 73591/(6721+15) = 10.925 Science Advances: 6814/(726+15) = 9.195 Developmental Cell: 3635/(372+38) = 8.865 PNAS: 55771/6468 = 8.622 Cell Reports: 13710/1866 = 7.347 eLife: 13222/1979 = 6.681 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96201620396, createdName=CR10, createdTime=Thu Dec 28 20:46:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2236836, encodeId=910d223683628, content=审稿速度:3.0 经验分享：12, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45909346082, createdName=ms8000001611048358, createdTime=Thu Nov 14 00:15:36 CST 2024, time=2024-11-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=867, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=483, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给我们的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=421, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省)]

2017-12-28 CR10

Nature Communications: 73591/(6721+15) = 10.925
Science Advances: 6814/(726+15) = 9.195
Developmental Cell: 3635/(372+38) = 8.865
PNAS: 55771/6468 = 8.622
Cell Reports: 13710/1866 = 7.347
eLife: 13222/1979 = 6.681

382 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2258525, encodeId=7b88225852589, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：代谢工程;合成生物学;发酵调控 经验分享：24号开始 Under Evaluation，26，28分别动了一下日期，今天31号还是Under Evaluation，点进去看发现Editor Evaluation Completed，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26e69688758, createdName=ms3000001687948380, createdTime=Mon Mar 31 15:13:14 CST 2025, time=2025-03-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248945, encodeId=d92c22489452e, content=在home页面显示Under Evaluation，但是点进去文章稿件名之后，显示Status: Reviewer Invited是已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Mon Jan 20 22:44:21 CST 2025, time=2025-01-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=550438, encodeId=32c7550438f6, content=Nature Communications: 73591/(6721+15) = 10.925 Science Advances: 6814/(726+15) = 9.195 Developmental Cell: 3635/(372+38) = 8.865 PNAS: 55771/6468 = 8.622 Cell Reports: 13710/1866 = 7.347 eLife: 13222/1979 = 6.681 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96201620396, createdName=CR10, createdTime=Thu Dec 28 20:46:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2236836, encodeId=910d223683628, content=审稿速度:3.0 经验分享：12, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45909346082, createdName=ms8000001611048358, createdTime=Thu Nov 14 00:15:36 CST 2024, time=2024-11-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=867, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=483, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给我们的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=421, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省)]

2024-11-14 ms8000001611048358 来自广东省

审稿速度:3.0
经验分享：12

57 0

[GetPortalCommentsPageByObjectIdResponse(id=2258525, encodeId=7b88225852589, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：代谢工程;合成生物学;发酵调控 经验分享：24号开始 Under Evaluation，26，28分别动了一下日期，今天31号还是Under Evaluation，点进去看发现Editor Evaluation Completed，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26e69688758, createdName=ms3000001687948380, createdTime=Mon Mar 31 15:13:14 CST 2025, time=2025-03-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248945, encodeId=d92c22489452e, content=在home页面显示Under Evaluation，但是点进去文章稿件名之后，显示Status: Reviewer Invited是已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Mon Jan 20 22:44:21 CST 2025, time=2025-01-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=550438, encodeId=32c7550438f6, content=Nature Communications: 73591/(6721+15) = 10.925 Science Advances: 6814/(726+15) = 9.195 Developmental Cell: 3635/(372+38) = 8.865 PNAS: 55771/6468 = 8.622 Cell Reports: 13710/1866 = 7.347 eLife: 13222/1979 = 6.681 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96201620396, createdName=CR10, createdTime=Thu Dec 28 20:46:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2236836, encodeId=910d223683628, content=审稿速度:3.0 经验分享：12, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45909346082, createdName=ms8000001611048358, createdTime=Thu Nov 14 00:15:36 CST 2024, time=2024-11-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=867, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=483, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给我们的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=421, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省)]

2020-06-13 ms3036779279854874

审稿速度:4.0
经验分享：20200127 投稿
20200327 第一轮修改，三个审稿人（两个小修，一个大修）
20200505 第一轮修改，三个审稿人（两个同意接收，一个小修）
20200528 accept-technical hold
20200602 付版面费 4500 usd
20200612 accepted
希望对投稿的人有所帮助！！！

867 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2258525, encodeId=7b88225852589, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：代谢工程;合成生物学;发酵调控 经验分享：24号开始 Under Evaluation，26，28分别动了一下日期，今天31号还是Under Evaluation，点进去看发现Editor Evaluation Completed，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26e69688758, createdName=ms3000001687948380, createdTime=Mon Mar 31 15:13:14 CST 2025, time=2025-03-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248945, encodeId=d92c22489452e, content=在home页面显示Under Evaluation，但是点进去文章稿件名之后，显示Status: Reviewer Invited是已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Mon Jan 20 22:44:21 CST 2025, time=2025-01-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=550438, encodeId=32c7550438f6, content=Nature Communications: 73591/(6721+15) = 10.925 Science Advances: 6814/(726+15) = 9.195 Developmental Cell: 3635/(372+38) = 8.865 PNAS: 55771/6468 = 8.622 Cell Reports: 13710/1866 = 7.347 eLife: 13222/1979 = 6.681 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96201620396, createdName=CR10, createdTime=Thu Dec 28 20:46:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2236836, encodeId=910d223683628, content=审稿速度:3.0 经验分享：12, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45909346082, createdName=ms8000001611048358, createdTime=Thu Nov 14 00:15:36 CST 2024, time=2024-11-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=867, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=483, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给我们的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=421, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省)]

2022-09-22 a201061519

偏重的研究方向：肿瘤
经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！

483 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2258525, encodeId=7b88225852589, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：代谢工程;合成生物学;发酵调控 经验分享：24号开始 Under Evaluation，26，28分别动了一下日期，今天31号还是Under Evaluation，点进去看发现Editor Evaluation Completed，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26e69688758, createdName=ms3000001687948380, createdTime=Mon Mar 31 15:13:14 CST 2025, time=2025-03-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248945, encodeId=d92c22489452e, content=在home页面显示Under Evaluation，但是点进去文章稿件名之后，显示Status: Reviewer Invited是已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Mon Jan 20 22:44:21 CST 2025, time=2025-01-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=550438, encodeId=32c7550438f6, content=Nature Communications: 73591/(6721+15) = 10.925 Science Advances: 6814/(726+15) = 9.195 Developmental Cell: 3635/(372+38) = 8.865 PNAS: 55771/6468 = 8.622 Cell Reports: 13710/1866 = 7.347 eLife: 13222/1979 = 6.681 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96201620396, createdName=CR10, createdTime=Thu Dec 28 20:46:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2236836, encodeId=910d223683628, content=审稿速度:3.0 经验分享：12, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45909346082, createdName=ms8000001611048358, createdTime=Thu Nov 14 00:15:36 CST 2024, time=2024-11-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=867, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=483, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给我们的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=421, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省)]

2020-04-13 ms313574960747337

审稿速度:10.0
经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。

407 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2258525, encodeId=7b88225852589, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：代谢工程;合成生物学;发酵调控 经验分享：24号开始 Under Evaluation，26，28分别动了一下日期，今天31号还是Under Evaluation，点进去看发现Editor Evaluation Completed，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26e69688758, createdName=ms3000001687948380, createdTime=Mon Mar 31 15:13:14 CST 2025, time=2025-03-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248945, encodeId=d92c22489452e, content=在home页面显示Under Evaluation，但是点进去文章稿件名之后，显示Status: Reviewer Invited是已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Mon Jan 20 22:44:21 CST 2025, time=2025-01-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=550438, encodeId=32c7550438f6, content=Nature Communications: 73591/(6721+15) = 10.925 Science Advances: 6814/(726+15) = 9.195 Developmental Cell: 3635/(372+38) = 8.865 PNAS: 55771/6468 = 8.622 Cell Reports: 13710/1866 = 7.347 eLife: 13222/1979 = 6.681 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96201620396, createdName=CR10, createdTime=Thu Dec 28 20:46:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2236836, encodeId=910d223683628, content=审稿速度:3.0 经验分享：12, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45909346082, createdName=ms8000001611048358, createdTime=Thu Nov 14 00:15:36 CST 2024, time=2024-11-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=867, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=483, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给我们的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=421, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省)]

2022-08-06 马疾香幽

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：免疫;肿瘤;生物信息
经验分享：第14天被拒。整体速度感觉偏慢吧。

470 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2258525, encodeId=7b88225852589, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：代谢工程;合成生物学;发酵调控 经验分享：24号开始 Under Evaluation，26，28分别动了一下日期，今天31号还是Under Evaluation，点进去看发现Editor Evaluation Completed，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26e69688758, createdName=ms3000001687948380, createdTime=Mon Mar 31 15:13:14 CST 2025, time=2025-03-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248945, encodeId=d92c22489452e, content=在home页面显示Under Evaluation，但是点进去文章稿件名之后，显示Status: Reviewer Invited是已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Mon Jan 20 22:44:21 CST 2025, time=2025-01-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=550438, encodeId=32c7550438f6, content=Nature Communications: 73591/(6721+15) = 10.925 Science Advances: 6814/(726+15) = 9.195 Developmental Cell: 3635/(372+38) = 8.865 PNAS: 55771/6468 = 8.622 Cell Reports: 13710/1866 = 7.347 eLife: 13222/1979 = 6.681 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96201620396, createdName=CR10, createdTime=Thu Dec 28 20:46:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2236836, encodeId=910d223683628, content=审稿速度:3.0 经验分享：12, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45909346082, createdName=ms8000001611048358, createdTime=Thu Nov 14 00:15:36 CST 2024, time=2024-11-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=867, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=483, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给我们的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=421, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省)]

2023-08-02 丹丹同学来自江苏省

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：医学;肿瘤
经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛

351 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2258525, encodeId=7b88225852589, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：代谢工程;合成生物学;发酵调控 经验分享：24号开始 Under Evaluation，26，28分别动了一下日期，今天31号还是Under Evaluation，点进去看发现Editor Evaluation Completed，是不是要被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26e69688758, createdName=ms3000001687948380, createdTime=Mon Mar 31 15:13:14 CST 2025, time=2025-03-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248945, encodeId=d92c22489452e, content=在home页面显示Under Evaluation，但是点进去文章稿件名之后，显示Status: Reviewer Invited是已经送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e406432489, createdName=ms8000001656880339, createdTime=Mon Jan 20 22:44:21 CST 2025, time=2025-01-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=550438, encodeId=32c7550438f6, content=Nature Communications: 73591/(6721+15) = 10.925 Science Advances: 6814/(726+15) = 9.195 Developmental Cell: 3635/(372+38) = 8.865 PNAS: 55771/6468 = 8.622 Cell Reports: 13710/1866 = 7.347 eLife: 13222/1979 = 6.681 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96201620396, createdName=CR10, createdTime=Thu Dec 28 20:46:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2236836, encodeId=910d223683628, content=审稿速度:3.0 经验分享：12, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45909346082, createdName=ms8000001611048358, createdTime=Thu Nov 14 00:15:36 CST 2024, time=2024-11-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=861823, encodeId=7f2786182372, content=审稿速度:4.0 经验分享：20200127 投稿 20200327 第一轮修改，三个审稿人（两个小修，一个大修） 20200505 第一轮修改，三个审稿人（两个同意接收，一个小修） 20200528 accept-technical hold 20200602 付版面费 4500 usd 20200612 accepted 希望对投稿的人有所帮助！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=867, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdbe5414035, createdName=ms3036779279854874, createdTime=Sat Jun 13 11:06:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089860, encodeId=4cc8208986067, content=偏重的研究方向：肿瘤 经验分享：Under evaluation 到底要多久呀？有没有大佬交流下经验，感激！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=483, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Thu Sep 22 23:41:03 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859385, encodeId=8076859385e6, content=审稿速度:10.0 经验分享：我的还惨。投稿6个月整，才开始外审。外审又一个月，完了就拒绝了。看审稿意见基本是肯定的，应该是个大修。之后appeal了一下。编辑部说除非审稿意见是错误的，没有机会大修，就完事了。整体看审稿人的水平连plant physiol审稿人水平不如。所以很赞同这就是个**期刊。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=407, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Mon Apr 13 11:25:31 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236847, encodeId=28dd123684e8c, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;生物信息 经验分享：第14天被拒。整体速度感觉偏慢吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Aug 06 00:55:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150964, encodeId=a7832150964d9, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：医学;肿瘤 经验分享：投稿NC杂志3天要我转投它的姊妹刊，我不愿意，想投这SA，送审机会大嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=351, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/13/70430ae1e7e0fc481e5ad3235d0e1916.jpg, createdBy=2b215328303, createdName=丹丹同学, createdTime=Wed Aug 02 19:18:54 CST 2023, time=2023-08-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2115400, encodeId=e30b211540026, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：基础实验 经验分享：10.15投稿 中间一周换一次日期 11.25送审 11.28更新to review 2022.12.23更新to review 2023.1.8更新to review 2023.1.12更新to review 2023.1.15更新to review 2023.1.29更新to review 2023.1.31更新to review 2023.2.3更新to review 2023.2.4更新to review 2023.2.8更新to review 2023.2.18 reject 这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给我们的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=421, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462106269, createdName=Candy啦, createdTime=Sun Feb 19 14:50:02 CST 2023, time=2023-02-19, status=1, ipAttribution=四川省)]

2023-02-19 Candy啦来自四川省

审稿速度:6.0 | 投稿命中率:5.0
偏重的研究方向：基础实验
经验分享：10.15投稿
中间一周换一次日期
11.25送审
11.28更新to review
2022.12.23更新to review
2023.1.8更新to review
2023.1.12更新to review
2023.1.15更新to review
2023.1.29更新to review
2023.1.31更新to review
2023.2.3更新to review
2023.2.4更新to review
2023.2.8更新to review
2023.2.18 reject
这个杂志真的很奇怪，拒稿是reviewer意见不够积极，发给我们的邮件里只有一个reviewer的意见，并且其中说的“recommend the paper for publication after revision”。目前大家商量了打算appeal一下吧！

421 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务